Previous 10 | Next 10 |
Data validates continued high radiation absorbed of 186 RNL in escalating doses to treat glioblastoma, maintaining safety and limiting brain and whole-body exposure Company will also present at upcoming BIO International Convention 2022 being held June 13-16 in San D...
AUSTIN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief E...
The following slide deck was published by Plus Therapeutics, Inc. in conjunction with this event. For further details see: Investor Day Presentation 2021
AUSTIN, Texas, April 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief...
Plus Therapeutics press release (NASDAQ:PSTV): Q1 GAAP EPS of -$0.19 misses by $0.01. The Company’s cash balance was $21.2 million at March 31, 2022, compared to $18.4 million at December 31, 2021. Shares -0.45%. For further details see: Plus Therapeutics GAAP EPS of -$0.19 misse...
First patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186 RNL for leptomeningeal metastases Closed in-licensing transaction for novel targeted radioembolic technology for the treatment of solid organ tumors Expanded ReSPECT-GBM clinical trial ...
Pharmaceutical company Plus Therapeutics (NASDAQ:PSTV) Q1 consensus EPS estimate is -$0.19 and consensus revenue estimate is $0M. Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward revision. PSTV will post Q1 results on Apr. 20 after market close. ...
AUSTIN, Texas, April 19, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it will di...
AUSTIN, Texas, April 14, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will...
AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the compan...
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
PLUS THERAPEUTICS Inc. Website:
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance paym...
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announce...